Class Certification Sought In Shareholder Suit Over COVID-19 Vaccine Statements
PHILADELPHIA — Shareholders in a securities class action against a biotechnology company and three of its senior executives, who allegedly misrepresented the company’s development and manufacturing capabilities for its COVID-19 vaccine...To view the full article, register now.
Already a subscriber? Click here to view full article